BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

UnknownOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Heart Failure
Interventions
DEVICE

BAROSTIM NEO™ System

Implantation of the BAROSTIM NEO™ System

Trial Locations (13)

12203

ACTIVE_NOT_RECRUITING

Berlin Charité & Deutschen Herzzentrum Berlin, Berlin

16321

ACTIVE_NOT_RECRUITING

Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau

22763

RECRUITING

Asklepios Klinik Altona, Hamburg

30625

ACTIVE_NOT_RECRUITING

Medizinische Hochschule Hannover, Hanover

32756

ACTIVE_NOT_RECRUITING

Lippe Klinikum, Detmold

35392

RECRUITING

Universitätsklinikum Gießen und Marburg, Giessen

37075

ACTIVE_NOT_RECRUITING

Herzzentrum Göttingen, Göttingen

50937

RECRUITING

Universitätsklinikum Köln Herzzentrum, Cologne

57072

ACTIVE_NOT_RECRUITING

Marienkrankenhaus Siegen, Siegen

60590

ACTIVE_NOT_RECRUITING

Uniklinik Frankfurt, Frankfurt

69120

RECRUITING

Uniklinik Heidelberg, Heidelberg

85049

ACTIVE_NOT_RECRUITING

Kardiologie im Klinikum Ingolstadt, Ingolstadt

93053

ACTIVE_NOT_RECRUITING

Universitätsklinikum Regensburg, Regensburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CVRx, Inc.

INDUSTRY

NCT02876042 - BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter